Blocks Final Pathway to Platelet Aggregation > 90 % Platelet Inhibition within 10 minutes 1 Protects during the delayed onset of oral P2Y 12 agents 2
Only GP IIb / IIIa Inhibitor with Short Infusion ACC / AHA / SCAI Class I Recommended 3 , 4
Learn how hospitals are saving on drug acquisition costs by using Aggrastat . Contact a Product Specialist : 1-800-509-0544 (# 5 ) or visit www . aggrastatHDB . com
FAST ON . FAST OFF .
Platelet Inhibition when you need it most .
Blocks Final Pathway to Platelet Aggregation > 90 % Platelet Inhibition within 10 minutes 1 Protects during the delayed onset of oral P2Y 12 agents 2
Only GP IIb / IIIa Inhibitor with Short Infusion ACC / AHA / SCAI Class I Recommended 3 , 4
IMPORTANT SAFETY INFORMATION
High-Dose Bolus ( HDB ) Regimen : Administer intravenously 25 mcg / kg within 5 minutes and then 0.15 mcg / kg / min for up to 18 hours . In patients with creatinine clearance ≤60 mL / min , give 25 mcg / kg within 5 minutes and then 0.075 mcg / kg / min .
Indication : Aggrastat is indicated to reduce the rate of thrombotic cardiovascular events ( combined endpoint of death , myocardial infarction , or refractory ischemia / repeat cardiac procedure ) in patients with non-ST elevation acute coronary syndrome ( NSTE-ACS ).
Contraindications : Known hypersensitivity to any component of Aggrastat ; history of thrombocytopenia with prior exposure to Aggrastat ; active internal bleeding , or history of bleeding diathesis , major surgical procedure or severe physical trauma within the previous month .
Please see Brief Prescribing Information on reverse .
Warnings and Precautions : Aggrastat can cause serious bleeding . If bleeding cannot be controlled discontinue Aggrastat ; thrombocytopenia : discontinue Aggrastat and heparin .
Adverse Reactions : Bleeding is the most commonly reported adverse reaction . You are encouraged to report negative side effects of prescription drugs to the FDA . Visit MedWatch or call 1-800-FDA-1088 .
References 1 . Mardikar HM et al . Am Heart J 2007 ; 154:344e1-5 2 . Goto S et al . J Am Coll Cardiol 2004 ; 44:316-323 3 . Levine GN et al . J Am Coll Cardiol 2011 ; 58 : e44-e122 4 . Amsterdam EA et al . J Am Coll Cardiol 2014 ; 64:2645-2687
Aggrastat is a registered trademark of Medicure Pharma . © 2016 Medicure Pharma . All rights reserved .
PA-TP-02
Learn how hospitals are saving on drug acquisition costs by using Aggrastat . Contact a Product Specialist : 1-800-509-0544 (# 5 ) or visit www . aggrastatHDB . com